肾癌治疗和诊断市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

肾癌治疗和诊断市场按癌症类型、成分(药物和诊断)和地理划分

市场快照

kidney
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 6.46 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

由于肾癌病例数量的增加和制药公司研发支出的增加,肾癌治疗和诊断市场将呈现快速增长。

  • 根据 GLOBOCAN 的数据,2018 年全球肾癌的发病率为 4.5/100,000。造成全球癌症病例的5个主要国家是中国、美国、俄罗斯、德国和日本。这些国家被发现是全世界肾癌发病率最高的国家。
  • 预计全球肾癌病例的增加将增加全球对早期治疗诊断方法的需求。根据美国癌症协会最近的估计,2019 年约有 73,820 例新的肾癌病例(男性 44,120 例,女性 29,700 例)。肾癌和肾盂癌占美国所有新发癌症病例的 4.2%。据估计,2019 年约有 14,770 人死于肾癌和肾盂癌。
  • 目前,有多种治疗方案可供选择,许多药物也在筹备中,预计将在预测期内推动肾癌治疗和诊断市场。
  • 此外,各政府机构对研究的投资增加以及制药和生物技术公司开发新药是其他主要因素。

报告范围

根据报告的范围,肾癌是一种始于肾细胞的癌症。肾癌治疗和诊断涉及用于治疗肾癌的治疗和诊断方法。这些药物用于治疗各种类型的肾癌。

By Cancer Type
Clear cell RCC
Papillary RCC
Chromophobe RCC
Urothelial carcinoma/Transitional cell carcinoma
Other Kidney cancers (Wilms tumor, Renal sarcoma, Collecting duct RCC)
By Component
Drugs
Therapeutic Class
Targeted Therapy
Immunotherapy
Other Therapeutic Class
By Pharmacologic Class
Angiogenesis Inhibitors
Monoclonal Antibodies
mTOR Inhibitors
Cytokine Immunotherapy (IL-2)
Diagnostics
Biopsy
Imaging Tests
Blood Tests
Other Diagnostics
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

透明细胞 RCC 有望成为肾癌治疗和诊断市场中增长最快的部分

  • 透明细胞肾细胞癌或 ccRCC 是一种肾癌。透明细胞肾细胞癌也称为常规肾细胞癌。透明细胞肾细胞癌以肿瘤在显微镜下的外观命名。肿瘤中的细胞看起来像气泡一样清晰。
  • 根据美国国家癌症研究所的数据,在成人中,ccRCC 是最常见的肾癌类型,约占所有肾细胞癌病例的 80%。ccRCC 在成人中比在儿童中更常见。肾细胞癌占儿童和年轻成人肾癌病例的 2% 至 6%。
  • ccRCC 患者可能会感到疼痛或感到疲倦。有时,患者没有任何明显的症状。症状可能包括尿血、疼痛、体重减轻、感觉疲倦、发烧和侧面肿块。
  • 对于没有症状的人,如果该人也进行了影像学检查,则可以发现这些肿瘤。另一种检测 ccRCC 的方法是活检。为了检查肿瘤是否为 ccRCC,医生会进行活检,用针从肿瘤中取出一小块样本。在显微镜下研究样本,看看它是什么类型的肿瘤。
  • ccRCC 患者的治疗包括手术、免疫治疗和靶向治疗。靶向治疗针对癌细胞的变化,帮助它们生长、分裂和扩散。一些用于治疗透明细胞肾癌的靶向疗法包括卡博替尼、阿西替尼、舒尼替尼、索拉非尼和帕唑帕尼。
  • 因此,随着疾病的高流行以及诊断程序和治疗疗法的存在,预计市场将出现增长。
Kidney cancer Stats - United States.png

发现北美引领肾癌治疗和诊断市场

北美主导着全球肾癌治疗和诊断市场。推动增长的主要因素是肾癌病例数量的增加。根据 GLOBOCAN 2018 年的统计数据,美国的肾癌患者估计数为 60,336。其他因素,如制药公司研发支出的增加和人口老龄化的增加,预计将导致预测期内市场的增长。

然而,预计亚太地区将成为预测期内增长最快的市场。肾癌患者群的增加、患者意识的提高和药物生产成本的降低预计将推动该市场的增长。

Picture2

竞争格局

已经有相当数量的公司为市场增长做出了重大贡献。产品创新和为开发先进技术而进行的持续研发活动有助于促进市场的增长。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Kidney Cancer

      2. 4.2.2 Increased R&D Expenditure of Pharmaceutical Companies

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost Associated with Treatment

      2. 4.3.2 Low Success Rate in Clinical Trials for Cancer Drugs

      3. 4.3.3 Regulatory Issues

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Cancer Type

      1. 5.1.1 Clear cell RCC

      2. 5.1.2 Papillary RCC

      3. 5.1.3 Chromophobe RCC

      4. 5.1.4 Urothelial carcinoma/Transitional cell carcinoma

      5. 5.1.5 Other Kidney cancers (Wilms tumor, Renal sarcoma, Collecting duct RCC)

    2. 5.2 By Component

      1. 5.2.1 Drugs

        1. 5.2.1.1 Therapeutic Class

          1. 5.2.1.1.1 Targeted Therapy

          2. 5.2.1.1.2 Immunotherapy

          3. 5.2.1.1.3 Other Therapeutic Class

        2. 5.2.1.2 By Pharmacologic Class

          1. 5.2.1.2.1 Angiogenesis Inhibitors

          2. 5.2.1.2.2 Monoclonal Antibodies

          3. 5.2.1.2.3 mTOR Inhibitors

          4. 5.2.1.2.4 Cytokine Immunotherapy (IL-2)

      2. 5.2.2 Diagnostics

        1. 5.2.2.1 Biopsy

        2. 5.2.2.2 Imaging Tests

        3. 5.2.2.3 Blood Tests

        4. 5.2.2.4 Other Diagnostics

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

    4. 5.4

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 Amgen Inc.

      3. 6.1.3 Bayer AG

      4. 6.1.4 BRISTOL-MYERS SQUIBB COMPANY

      5. 6.1.5 F. Hoffmann-La Roche

      6. 6.1.6 Merck & Co. Inc.

      7. 6.1.7 Merck KGaA (EMD Serono)

      8. 6.1.8 Novartis International AG

      9. 6.1.9 Pfizer Inc.

      10. 6.1.10 Seattle Genetic

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Kidney Cancer Therapeutics & Diagnostics Market market is studied from 2018 - 2026.

The Kidney Cancer Therapeutics & Diagnostics Market is growing at a CAGR of 6.46% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Amgen Inc., Bayer AG, F. Hoffmann-La Roche, ABBOTT LABORATORIES , BRISTOL-MYERS SQUIBB COMPANY are the major companies operating in Kidney Cancer Therapeutics & Diagnostics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!